Abbott's AVEIR DR™ LP System received FDA approval in 2023. It is designed to treat abnormal or slow heart rhythms, also known as arrhythmia. Left untreated, arrhythmia can lead to serious complications, including stroke and heart failure.

The AVEIR DR™ LP System’s innovative design eliminates the need for leads or wires while avoiding chest incisions for generator placement. Comprised of an atrial leadless pacemaker (AVEIR™ AR LP) and a ventricular leadless pacemaker (AVEIR™ VR LP), the device enables pacing and sensing in both chambers of the heart. Physicians can start with an atrial or ventricular device alone and then add a second pacemaker for dual chamber support if needed.

"Physicians need the flexibility to adjust treatment as patient needs evolve," said Dr. Sinno. "This device enables us to do just that for our cardiac patients while also eliminating common complications associated with traditional pacemakers, including infection, lead fracture, insulation problems, skin erosion and keloid formation."

After the device is implanted, patients experience no visible scarring and do not have any restrictions on arm movement, which improves their short-term recovery compared to a traditional pacemaker.

"We're proud to lead the way in the Greater Cincinnati region by offering this life-saving device," said Dr. D.P. Suresh, Executive Medical Director of the Florence Wormald Heart & Vascular Institute at St. Elizabeth. "We are committed to providing our patients with the latest technology and treatments, and the AVEIR DR™ is a prime example of our dedication to advancing patient care and experience."

To learn more about cardiology services offered at St. Elizabeth Healthcare, visit stelizabeth.com or call 859-331-3353.